Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $110
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Yanan Zhu maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $87 to $110.
Wells Fargo analyst Yanan Zhu maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $87 to $110.